7:30 am Check-In & Coffee
8:30 am Chair’s Opening Remarks
Comparing CAR-T & Emerging Modalities to Guide Modality Selection & Refine Therapeutic Strategy
8:40 am Industry Leaders Fireside Chat: What’s Happened in the Last Year & Where is the Field Going?
Synopsis
- Explore the efficacy of differing modalities to identify opportunities to leverage key development strategies
- Compare modalities in their affinity for targeting autoreactive cells to minimize side-effects and enhance safety
- Consider indication selection strategies and the potential for indication diversification beyond lupus
9:30 am Keynote Presentation: Showcasing Cabaletta Bio’s Rese-cel Data & Industry Implications to Progress CAR-T in Autoimmunity
Synopsis
- Explore rese-cel, a CAR-T cell therapy, combating autoimmune diseases to provide insight into the future of autoimmune cell therapies
- Discuss how translational and mechanistic insights accelerated the design and development of rese-cel in autoimmunity
- Evaluate the depth of peripheral and tissue-level target cell depletion with rese-cel in patients with autoimmune disease
10:00 am Could Artiva’s NK cells drive cell therapy-like activity with biologics-like ease of use?
Synopsis
- Highlight the rationale and potential advantages of utilizing a non-genetically modified NK cell therapy in combination with monoclonal antibodies in autoimmune diseases
- Explore clinical data demonstrating that NK cell therapies can drive deep B-cell depletion in autoimmune disease while avoiding side effects inherent in CAR-T and TCE therapies
- Highlight a framework for selecting indications for different cell therapies based on their potential target product profile
10:30 am Morning Break & Speed Networking
Synopsis
As this community reunites, this session will provide valuable networking time with your peers, and new faces in the autoimmune space, enabling you to forge new and lasting connections.
Preclinical & Translational
Investigating Next-Generation Antibody Targeting Strategies to Enhance Precision & Efficacy
11:30 am Expanding CAR-T Targets Beyond CD-19 to Enhance Treatment Efficacy Across Autoimmune Diseases
Synopsis
- Evaluate CD-19’s strengths and limitations as the anchor target for CAR-T treatment of autoimmune diseases
- Explore novel targets to broaden the spectrum and complexity of treatable autoimmune diseases
- Evaluate available targeting options to pinpoint optimal targets for varying autoimmune and autoinflammatory diseases
12:00 pm Targeted Cell Killing Bioassays for CAR-T Potency Assessment
Synopsis
- Developing potency assays that demonstrate antigen-specific CAR-T function for address regulatory needs
- Improving the sensitivity of cytotoxicity readouts using luminescence based approach
- Confirming specificity and functional activity using knockout target cell lines (e.g., CD-19, CD-20)
Clinical
Exploring Immune Cell Targeting to Enhance Treatment Efficacy & Durability
11:30 am Optimizing Immune Cell Target Selection to Deliver Effective Autoimmune Therapies
Synopsis
- Evaluate which immune cell targets have demonstrated the greatest therapeutic benefits to guide treatment decisions
- Understand patient tolerance to targeting alternative immune cells to optimize safety and efficacy
- Leverage insights from Nkarta Therapeutics’ NK cell-based Non-Hodgkins Lymphoma therapy to predict autoimmune success
12:00 pm Enhancing cell therapy manufacturing: Flexible solutions for CAR T production
Synopsis
- Introducing a rapid 18-hour process for autologous CAR-T therapy using Lupus patient material
- Demonstrates potent cytotoxicity and expansion potential of the cryopreserved cells
- Explore flexible options for every workflow
12:10 pm Lunch & Networking Break
Exploring Innovations in B-Cell Depletion & Beyond to Advance Immune Modulation
1:10 pm Exploring Autologous CD-19 CAR-Tregs for Rheumatology to Advance Treatment Development for Unmet Diseases
Synopsis
- Explore the role of the immune system in rheumatoid scleroderma
- Hear preclinical evidence from Quell Therapeutics on their novel therapy targeting rheumatoid scleroderma
1:40 pm Panel Discussion: Comparing Immune Cell Depletion & Immune Tolerance Therapies to Accelerate Safer, Efficacious Therapies
Synopsis
- Expand therapeutic approaches beyond B-cell depletion
- Highlight safety challenges with depletion in comparison to tolerance with Tregs
- Explore the long-term biological effects of B-cell depletion and immune reprogramming therapies
Optimizing Immune Cell Depletion Strategies to Enhance Safety, Persistence & Long-Term Remission in Autoimmune Therapies
1:10 pm Advancing T-Cell-Targeted Therapies for Autoimmune Diseases to Unlock More Precise & Durable Treatment Options
Synopsis
- Explore T-cell targeting strategies to combat SLE and improve therapeutic outcomes
- Examining Novartis’ srSLE CAR-T data to uncover insights into novel CAR-T approaches to address unmet medical needs
- Highlight Novartis’ novel CAR-T manufacturing platform (T-Charge) to evaluate its impact on enhancing T-cell targeted treatments for autoimmune diseases
1:40 pm Panel Discussion: Utilizing Biomarkers to Sustain Durable Responses in Autoimmune Therapies
Synopsis
- Identifying biomarker differences across indications and modalities
- Harness specific biomarkers to effectively identify patient response, manage patient safety and enhance patient selection
- Explore the use of biomarkers to determine optimal timing for re-dosing and sustaining efficacy
2:40 pm Afternoon Break & Poster Session
Synopsis
This is your opportunity to contribute to the conversation and share your cutting-edge research with this community, while discovering exciting work carried out by your peers. To submit a poster, please contact info@hansonwade.com.
Delving into Cell Therapy Innovations to Explore the Future of Autoimmune Cell Therapies
3:30 pm Demonstrating Durable Remission in Lupus with iCell Gene Therapeutics’ Dual-Target, Armored CAR-T Therapy
Synopsis
- Introducing iCell Gene Therapeutics’ ICG318 CD-19—BCMA/IL-15 compound CAR-T
- Evaluate the synergistic impact of combined B-cell and plasma cell depletion in enhancing durability of response
- Highlight iCell Gene Therapeutics’ 5+ year long-term follow-up data, to define what therapeutic durability looks like in lupus patients
4:00 pm VivoVec™ Generates Potent CAR-T-Cells In Vivo For the Potential Treatment of Autoimmune Diseases & Cancers
Synopsis
- Umoja is developing the VivoVec™ platform of therapeutics designed to be administered directly to patients resulting in the generation of CAR-T-cells in vivo to treat autoimmune diseases and cancers
- Modeling in non-human primates has demonstrated the ability of VivoVec™ to generate highly functional B-cell targeting CAR-T-cells in vivo that drive B-cell depletion and immune reset
- Umoja is evaluating multiple VivoVec™ in vivo CAR-T-cell products in the clinic in autoimmune disease and B-cell malignancies
4:30 pm Advancing In Vivo RNA Therapies Towards Clinical in B-Cell-Mediated Autoimmune Diseases
Synopsis
- Share data highlighting the benefits of in vivo therapies in autoimmune diseases
- Share NHP preclinical data highlighting the benefits of in vivo RNA therapy
- Highlight the development of in vivo CAR-T therapy for the clinic